Clinical Trial Update: Danish Observational Study of Everolimus Plus Exemestane in Hormone Receptor (HR) Positive, Human Epidermal Growth Factor 2 (HER2) - Metastatic Breast Cancer

View source ↗

Summary

This entry reports the completion of a Danish observational study evaluating everolimus plus exemestane in HR-positive, HER2-negative metastatic breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone Receptor-positive Metastatic Breast Cancer

Drugs mentioned

• Everolimus (everolimus)
• Exemestane (Exemestane)

Snippet

Sponsor: Novartis Healthcare A/S | Conditions: Breast Cancer | Status: COMPLETED